<?xml version='1.0' encoding='utf-8'?>
<document id="29846137"><sentence text="A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies."><entity charOffset="33-42" id="DDI-PubMed.29846137.s1.e0" text="ibrutinib" /></sentence><sentence text="This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations"><entity charOffset="105-114" id="DDI-PubMed.29846137.s2.e0" text="ibrutinib" /><entity charOffset="129-141" id="DDI-PubMed.29846137.s2.e1" text="erythromycin" /><entity charOffset="155-167" id="DDI-PubMed.29846137.s2.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.29846137.s2.e0" e2="DDI-PubMed.29846137.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29846137.s2.e0" e2="DDI-PubMed.29846137.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s2.e0" e2="DDI-PubMed.29846137.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29846137.s2.e1" e2="DDI-PubMed.29846137.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s2.e1" e2="DDI-PubMed.29846137.s2.e2" /></sentence><sentence text=" During cycle 1, patients received oral ibrutinib 560 mg qd alone (Days 1-4 and 14-18), and ibrutinib 140 mg (Days 5-13; 19-27) plus erythromycin 500 mg tid (Days 5-11) and voriconazole 200 mg bid (Days 19-25)"><entity charOffset="40-49" id="DDI-PubMed.29846137.s3.e0" text="ibrutinib" /><entity charOffset="92-101" id="DDI-PubMed.29846137.s3.e1" text="ibrutinib" /><entity charOffset="133-145" id="DDI-PubMed.29846137.s3.e2" text="erythromycin" /><entity charOffset="173-185" id="DDI-PubMed.29846137.s3.e3" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e0" e2="DDI-PubMed.29846137.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e0" e2="DDI-PubMed.29846137.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e0" e2="DDI-PubMed.29846137.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e0" e2="DDI-PubMed.29846137.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e1" e2="DDI-PubMed.29846137.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e1" e2="DDI-PubMed.29846137.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e1" e2="DDI-PubMed.29846137.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e2" e2="DDI-PubMed.29846137.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29846137.s3.e2" e2="DDI-PubMed.29846137.s3.e3" /></sentence><sentence text=" Twenty-six patients (median [range] age: 64" /><sentence text="5 [50-88] years) were enrolled" /><sentence text=" Geometric mean ratio (90% confidence intervals) after co-administration of ibrutinib 140 mg with erythromycin and voriconazole was 74"><entity charOffset="76-85" id="DDI-PubMed.29846137.s6.e0" text="ibrutinib" /><entity charOffset="98-110" id="DDI-PubMed.29846137.s6.e1" text="erythromycin" /><entity charOffset="115-127" id="DDI-PubMed.29846137.s6.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.29846137.s6.e0" e2="DDI-PubMed.29846137.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29846137.s6.e0" e2="DDI-PubMed.29846137.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s6.e0" e2="DDI-PubMed.29846137.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29846137.s6.e1" e2="DDI-PubMed.29846137.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s6.e1" e2="DDI-PubMed.29846137.s6.e2" /></sentence><sentence text="7 (53" /><sentence text="97-103" /><sentence text="51) and 143" /><sentence text="3 (107" /><sentence text="77-190" /><sentence text="42), respectively, versus ibrutinib 560 mg alone"><entity charOffset="26-35" id="DDI-PubMed.29846137.s12.e0" text="ibrutinib" /></sentence><sentence text=" The most common (≥20%) adverse events were diarrhea (27%) and neutropenia (23%)" /><sentence text=" The results demonstrate that ibrutinib 140 mg with voriconazole or erythromycin provides exposure within the clinical range for patients with B-cell malignancies"><entity charOffset="30-39" id="DDI-PubMed.29846137.s14.e0" text="ibrutinib" /><entity charOffset="52-64" id="DDI-PubMed.29846137.s14.e1" text="voriconazole" /><entity charOffset="68-80" id="DDI-PubMed.29846137.s14.e2" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.29846137.s14.e0" e2="DDI-PubMed.29846137.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29846137.s14.e0" e2="DDI-PubMed.29846137.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s14.e0" e2="DDI-PubMed.29846137.s14.e2" /><pair ddi="false" e1="DDI-PubMed.29846137.s14.e1" e2="DDI-PubMed.29846137.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29846137.s14.e1" e2="DDI-PubMed.29846137.s14.e2" /></sentence><sentence text="" /></document>